Loading…
Clinical Implication of Drug Resistance for H. pylori Management
Rates of antimicrobial-resistance among strains are increasing worldwide, resulting in declining eradication rates with current therapies, especially those containing clarithromycin or levofloxacin. To improve management, a paradigm shift is needed, from the empiric approaches formerly employed, to...
Saved in:
Published in: | Antibiotics (Basel) 2022-11, Vol.11 (12), p.1684 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Rates of antimicrobial-resistance among
strains are increasing worldwide, resulting in declining eradication rates with current therapies, especially those containing clarithromycin or levofloxacin. To improve
management, a paradigm shift is needed, from the empiric approaches formerly employed, to regimen selection based upon knowledge of local and patient-level antimicrobial susceptibility data. We review the mechanisms of
antimicrobial resistance and the available worldwide pattern of resistance to key antimicrobials used in
therapy. The practicalities and challenges of measuring susceptibility in clinical practice is discussed, including not only conventional culture-based techniques but also novel sequencing-based methods performed on gastric tissue and stool samples. Though clinical trials of "tailored" (susceptibility-based) treatments have yet to show the clear superiority of tailored over empiric regimen selection, the ability to measure and modify treatment based upon antimicrobial susceptibility testing is likely to become more frequent in clinical practice and should lead to improved
management in the near future. |
---|---|
ISSN: | 2079-6382 2079-6382 |
DOI: | 10.3390/antibiotics11121684 |